News

Anton Lavrentev took part in the discussion on the “Direct and Venture Investment Funds as a Key Tool in Financing Digital Economy” held by the Analytics Center for the Government of the Russian Federation.

Primer Capital Venture Fund invested in a US-based company. The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases. The portfolio of Primer Capital now includes 11 projects from Russia, USA, Israel and France.

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.

Primer Capital has been awarded the Best Biotech VC Fund – Europe by Wealth & Money Management Awards 2019.

The founder of Data MATRIX (Primer Capital's portfolio project) entered the ranking of the top 20 most successful MedTech entrepreneurs according to RusBase. 

Anton Lavrentev, head of the legal department at Primer Capital, in his interview for VC.ru talked about ethical components which are essential for investors to consider before taking on new target. 

Sergei Sorokin, the founder of Botkin AI project, a Primer Capital's portfolio unit, and an expert in IT solutions for medicine shared his views on AI within Russian healthcare system with HighTech. 

Botkin.AI, Primer Capital’s portfolio unit, raised a round A of investments for the development of the artificial intelligence (AI) platform for cancer detection.

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.